Nazca Capital, a mid-market private equity fund in Spain, completed the acquisition of a 85% stake in Diater, a Spanish biopharmaceutical company, pioneer in the field of allergy treatment with immunotherapy, for €45m. In this new stage, Nazca together with the management team will develop an expansion plan focused on Diater strong R&D capabilities, developing new diagnosis products and immunotherapy treatments, and servicing new market segments, both nationally and internationally.